By Liz Moyer Investing.com -- Stocks were falling on Monday as investors prepared for the Federal Reserve's next decision on interest rates on Wednesday plus a slew of earnings reports from...
- Day's Range
- 43.40 - 44.13
- 52 wk Range
- 41.44 - 56.32
- Prev. Close
- Average Vol.(3m)
- 1-Year Change
- Market Cap
- P/E Ratio
- United States
- Shares Outstanding
- Dividend (Yield)
- 1.64 (3.65%)
- Next Earnings Date
- Jan 31, 2023
By Senad Karaahmetovic U.S. futures are moving lower in premarket Monday as investors brace for another busy week. The Federal Reserve meeting is the key event and the biggest catalyst for...
UBS downgraded Pfizer Inc (NYSE:PFE) to Neutral from Buy and cut its price target to $47.00 from $55.00 on Covid-related headwinds and its view that the company's pipeline is "not quite...
By Sam Boughedda Pfizer (NYSE:PFE) was downgraded to Neutral from Buy with its price target cut to $47 from $55 by UBS analysts on Thursday. The analysts told investors in a research...
By Davit Kirakosyan Pfizer (NYSE:PFE) shares closed more than 3% lower today after Wells Fargo downgraded the company to Equal Weight from Overweight and cut its price target to $50.00...
By Sam Boughedda Wells Fargo analysts downgraded shares of Pfizer (NYSE:PFE) to Equal Weight from Overweight, cutting the firm's price target on the stock to $50 from $54 per share in a...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, January 17th. Please refresh for updates. Goldman Sachs (NYSE:GS) stock fell 2.4% after the investment bank's...
By Sam Boughedda Pfizer (NYSE:PFE) management presented at an investor conference yesterday and Chief Executive Albert Bourla is said to have reiterated plans for shaping Pfizer...
By Sam Boughedda Morgan Stanley analysts labeled Moderna (NASDAQ:MRNA) a Catalyst Driven Idea in a note Friday, maintaining an Equal-Weight rating and $209 price target on the stock. The...
By Sam Boughedda In a note to clients Friday, Morgan Stanley analysts said the firm sees downside risk to Pfizer's (NYSE:PFE) EPS guidance. The analysts explained that Pfizer will...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.